NCT02082860 - Phase I Gene Therapy Clinical Trial Using the Vector rAAV2/5-PBGD for the Treatment of Acute Intermittent Porphyria | Biotech Hunter

Enrollment

Participants

Timeline

Start Date

November 30, 2012

Primary Completion Date

July 31, 2014

Study Completion Date

November 30, 2014

Conditions

Acute Intermittent Porphyria

Interventions

GENETIC

rAAV2/5-PBGD vector dosage 1

Intravenous injection of rAAV2/5-PBGD vector, single administration on Day 1.

GENETIC

rAAV2/5-PBGD vector dosage 2

Intravenous injection of rAAV2/5-PBGD vector, single administration on Day 1.

GENETIC

rAAV2/5-PBGD vector dosage 3

Intravenous injection of rAAV2/5-PBGD vector, single administration on Day 1.

GENETIC

rAAV2/5-PBGD vector dosage 4

Intravenous injection of rAAV2/5-PBGD vector, single administration on Day 1.

Trial Locations (2)

12 Octubre Hospital, Madrid

Clinica Universidad de Navarra, Pamplona